Xarelto: Can it compete with Eliquis

Discussion in 'Johnson & Johnson' started by Anonymous, Oct 22, 2011 at 4:41 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    But are you pointing at the sales aid and closing your doctors for action then sending in fake success stories.? This industry is so stupid, I'm getting out soon.

     

  2. Anonymous

    Anonymous Guest

    total mortality indication?
     
  3. Anonymous

    Anonymous Guest

    You can't have an indication with a secondary endpoint!
    We don't have the perfect study design but who care? At the end of the day, the physicain don't want a more powerful agent, he just want replace Coumadin and the monitoring.
     
  4. Anonymous

    Anonymous Guest

    Of course you cant get a total mortaility indication (unless you have an immortality drug, I suppose), but you CAN get it mentioned in the label. And if its in label, its on sales pieces. And docs like to know that they can count on continued revenue from 10% more of their patients because they are STILL ALIVE.

    Xarelto reps need to stop and listen - that pounding sound is the footsteps behind you.
     
  5. Anonymous

    Anonymous Guest

    Docs don't care abt replacing or monitoring. It's abt outcomes and safety.
     
  6. Anonymous

    Anonymous Guest

    oh and its all abt cost.